Biotech

(TheNewswire)



Vancouver, BC TheNewswire - September 10, 2021 Solarvest BioEnergy Inc. (" Solarvest " or the " Company ") (TSXV:SVS) held its annual general meeting of shareholders (the " Meeting ") on Wednesday, September 8. A total of 19,294,920 common shares (representing 34.87% of all issued and outstanding common shares of the Company) were represented at the Meeting. Shareholders of the Company (the " Shareholders ") voted in favor of all items of business put forth at the Meeting.

  • - The number of Directors for the Company was set at three (3).

    - The three members elected to the Board of Directors include: Gerri Greenham, William Cheliak and Gregory Drohan.

    - ArsenaultBestCameronEllis, Chartered Accountants, was re-appointed as auditor of the Company for the ensuing year.

    - The Company's Stock Option Plan was approved and ratified.

About Solarvest:

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully developed, patented and produced the world's only plant-based organic certified Omega -3 to satisfy the substantial demand for this essential nutrient.  The company has also initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

Solarvest BioEnergy

Solarvest BioEnergy

Overview

The global nutraceuticals market is expected to grow at a CAGR of 9.3 percent, with the potential to reach a market value of $658.11 billion by 2028. Nutraceuticals refer to medicinally or nutritionally functional consumables that include herbal remedies, nutritional supplements and fortified foods, among many other things. The nutraceuticals market was valued at US$320 billion in 2020 alone.

Among all nutraceutical products, Omega-3 fatty acids products are the most popular around the world. Omega-3 fatty acids have a myriad of potential benefits for human health including reducing the risk of cardiovascular disease, improving brain growth and development, reducing inflammation in the body and reducing the risk of cancer –– just to name a few. Based on these potential benefits, it’s no wonder that the global market for Omega-3 products was valued at US$44 billion in 2020.

Solarvest BioEnergy (TSXV:SVS) is an innovative Canadian technology development company focused on producing a wide range of patented algae-derived products including Omega-3 supplements and therapeutic proteins. The company plans to deliver solutions in human and animal nutrition, prescription and non-prescription medication and derivatives through its proprietary clean energy algal production platform. Solarvest BioEnergy is led by a highly experienced management team with nuanced expertise and a proven track record of achievements in developing commercial biotech products.

Technologies

Organic Omega: Solarvest BioEnergy’s algal production process allows for replicable, consistent and high-yield concentrations of final products for expedited product development and complex product versatility. It sustainably and efficiently produces organic certified Omega-3 fatty acids with five days of production resulting in tons of biomass. The company has produced the first and only FDA-approved DHA/EPA Organic Omega-3 supplement that is certified organic, vegan, allergen and pollution free, highly bioavailable, sustainable and non-GMO. Solarvest BioEnergy’s key consumer brand is called EverseaTM which brings the company’s first commercialized Organic Omega-3 products to market. The company’s Organic Omega-3 product(s) are plant based (from algae) so completely free of fish, unlike the majority of options in the market. The Organic Omega-3 product(s) is also available on the market white label.

Protein Expression: Solarvest BioEnergy has announced a successful proof of concept study for producing therapeutic proteins from algae. The first protein, bone morphogenetic protein (BMP6) is a highly valuable and complex protein that is used in human medicine to accelerate healing and enhance bone growth. Unlike current market options, the company’s BMP6 is safe as algae are free of any known human pathogens. The company is confident that it can produce other proteins. Solarvest BioEnergy will market its BMP6 and other potential proteins as approved pharmaceutical ingredients to large pharmaceutical companies.

The company has completed a feasibility study and implemented a research and development program to expand its product portfolio to include THC and CBD products. Solarvest BioEnergy believes that it can produce CBD from algae with its SVS algal expression platform. Compared to current CBD production methods, algal-based production will be significantly faster, higher quality, safer and since its produced in sterile bioreactors more controllable when compared to conventional agriculture.

H2 Expression: The company’s proprietary microalgae induction technology converts carbon dioxide and other nutrient waste streams into useful biomass and hydrogen

Solarvest BioEnergy has organized contract manufacturing for the commercial production of its Organic Omega-3 products. The company has secured an organic certified contract manufacturer from a German multi-billion dollar food company. Solarvest is also currently looking into the possibility of domestic production to build out the supply chain from its existing research and development facility in Prince Edward Island in Canada. The company also recently entered into a contract with Canada’s Smartest Kitchen to produce an ingredient blend for the plant-based seafood industry.

Solarvest BioEnergy has already filed 68 patents in commercially relevant markets including Europe, the US, Canada, Japan, China and Australia –– many of which have already been granted. In addition to Eversea’s e-commerce platform, the company plans to pursue a global penetration strategy by making strategic partnerships with organic food processors who to sell into large retailers and e commerce sites. This includes selling their Organic Omega-3 product as an additive or enhancement to organic food products such as dairy goods and smoothies sold by other companies. Given the importance of Omega-3 in brain development in babies and young children, the company will also market to the global infant and baby food segments.

Company Highlights

  • Solarvest BioEnergy is an innovative Canadian technology development company focused on producing a wide range of patented algae-derived products for human and animal nutrition, prescription and non-prescription medication and derivatives.
  • Solarvest BioEnergy’s key consumer brand is called Eversea which brings the company’s first commercialized Organic Omega-3 product to market. The product is the first and only FDA-approved DHA/EPA Organic Omega-3 supplement that is certified organic, vegan, non-toxic, highly bioavailable, sustainable and non-GMO. It will be sold through strategic partnerships and white label selling.
  • The company’s proprietary clean microalgae process allows for expedited product development and versatility to produce multiple complex products.
  • Solarvest BioEnergy’s production technology successfully produced highly valuable and safe bone morphogenetic protein (BMP).
  • The company has a strong market growth strategy. The company plans to expand its product human therapeutic CBD and THC products.
  • Solarvest BioEnergy is led by a highly experienced management team with expertise and a proven track record of achievements in developing commercial biotech products.

Key Products

Eversea

Eversea is Solarvest BioEnergy’s consumer brand of products. Eversea has brought the company’s Organic Omega-3 supplement to market through its e-commerce platform on its website. The product features a unique and patented Nanuq Organic Omega-3 ingredient which is certified organic in the European Union and by the USDA.

The Omega-3 supplement comes in the form of a dried fruit gummy that includes the companies patented long-chain Omega-3 which is significantly more bioavailable than current plant organic Omega-3 options which are short-chain. Known as ALA, (from Flax chia hemp) and only allow for less than 10 percent bio-absorption.

It is also pure with no solvents or chemicals such as hexane and acetone that are often used to extract Omega-3 oil from fish and krill. The Omega-3 supplement is also free of toxins and heavy metals such as mercury, PCBs and dioxins that are found in fish from the ocean. It is also completely free of fish and derived from algae which eliminate the risk of ocean-based contamination and saves dwindling native fish populations.

Eversea will bring to market various products that the company plans to release. Algae powder products will come in the forms of a processed food supplement, human nutraceutical, infant and baby food and a children’s supplement. Algae oil and beverage supplementation products will be human nutraceuticals. Pharmaceutical-grade oil will come in the form of an active ingredient and a carrier for bioactive products.

Management Team

Gerri Greenham — CEO and Director

Gerri Greenham has been active in the biotech industry since 1983. He organized the acquisition from Connaught Laboratories of their biotech division to create Cobequid Life Sciences Inc. (TSE: KQR) that was subsequently acquired by Novartis Animal Health Inc. (“Novartis”) in 2000. Since then, he has been involved in private investments as well as sitting on boards of directors and advisory boards of various public and private companies.

Dr. Azoy Kumar Kundu — Senior Research Scientist

Azoy Kumar Kundu obtained his bachelor’s degree in Agriculture from Bangladesh Agricultural University. He completed his M.S. and Ph.D. degrees from Japanese universities on plant viruses and carried out his postdoctoral research at JIRCAS in Japan. Before joining Eversea Inc., Kundu served at AquaBounty Canada Inc. as a senior research scientist. Kundu developed PCR-based diagnostic assays to differentiate the genetically modified Atlantic salmon (GMO salmon) from the wild-type Atlantic salmon and validated several important studies for AquaBounty. Kundu has completed “Good Laboratory Practice Study Director/Principal Investigator Training” from the Society of Quality Assurance in the United States. Kundu has experience in molecular biology, cell biology, protein chemistry-based research works, a wide range of laboratory techniques and analytical instrumentation. Experience in these fields enables him to perform high-value protein expression studies in microalgae.

Garth Greenham — COO

Garth Greenham has an extensive record with both privately-held and publicly traded healthcare companies. He served as president of the global aquaculture division at Novartis Inc. He started his career with Johnson & Johnson (J&J) where he served 15 years mostly with McNeil Pharmaceutical in numerous management positions in operations. He joined Cobequid Life Sciences Inc. (KQR) and served as director of sales and marketing and operations for nine years. Greenham helped grow Cobequid Life Sciences to become a global leader in the field of aquaculture animal vaccines.

Dr. Michael Thomas Horne BA Ph.D. FRSB FCIM FIBMS CBiol CSci CMgt — Head of Research

Dr. Michael Horne is a Fellow of Royal Society of Biology (UK), Fellow of Institute Biomedical Scientists and a Fellow of the Chartered Institute of Management is Solarvest’s Head of Research. Horne obtained a first degree and Ph.D. in genetics at the Universities of Oxford and Wales (UCNW). He later taught genetics at UCNW and then at Stirling University where he was the head of genetics and director of the aquatic vaccine unit. He joined the Canadian company Cobequid Life Sciences Inc. (KQR) as a director of research, developing over 40 licensed products for aquaculture for 20 years. On the acquisition of KQR by Novartis, he remained the director of research and development. Throughout this period, he held a number of non-executive positions and directorships in companies. He also acted on the advisory panel of the Scottish Development Agency and worked with various UK national scientific committees and The Irish Board of Medicines. Before moving into the industry, he was the author of 65 peer-reviewed publications and many more articles, presentations and contributions to general journals. He is also an author and co-author of a number of issued patents.

European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy® for the Treatment of HIV in Pediatric Populations

EC Authorizes a Low-Dose Tablet for HIV Treatment in Virologically Suppressed Children at Least Two Years of Age and Weighing at Least 14 kg, Helping to Address a Critical Unmet Need –

– Biktarvy Provides an Effective Therapy Choice for a Diverse Range of People Living with HIV, including Children with Limited Treatment Options –

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Collaboration will leverage Envisagenics' SpliceCore® AI platform for accelerated discovery and development of oncology therapeutic candidates

Envisagenics an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY). The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Komo Reports Fiscal Year 2022 Financial Results

Komo Reports Fiscal Year 2022 Financial Results

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ("Komo"), a premium plant-based food company, today reports financial results for the year ended July 31, 2022.

"We began our fiscal year as a new brand with a mission to make plant-based meals a staple on every dinner table by sharing our love for feel-good food that connects the people to the planet. Thanks to the strength of our team and the love of Komo products, we were successful in achieving sales growth of 935 percent over last year," says Komo founder and CEO William White. "The consistently strong retail sales of our products have allowed us to demonstrate to large retail chains that our products sell well and have repeat customers. We recently completed a national listing with Loblaws and we are in discussions with several other large national chains. As a result, we are anticipating continued significant revenue increases in 2023."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Grant of Stock Options

The Gummy Project Announces Grant of Stock Options

The Gummy Project Inc. (CSE: GUMY) (FSE: 0OS0) (OTCQB: GUMYD) ("GUMY" or the "Company") announces that it has issued a total of 2,300,000 stock options pursuant to its incentive stock option plan ("Plan") to consultants which vest on the grant date. Each option entitles the holder to subscribe for one common share of the Company for $0.06 for a period of 5 years, subject to the terms of the Plan. Over the past quarter, 1,664,800 options have lapsed or been cancelled.

About The Gummy Project

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday Dec. 5, 2022. David M. Reese M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team, will discuss the Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.

The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer

Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy Arm in First-Line NSCLC Patients –

Data will be Presented on December 20, 2022 at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×